LumiPath, Inc. develops a minimally invasive biopsy sampling system for routine use during colposcopy, enabling earlier detection and intervention of cervical lesions. By integrating this workflow into standard cervical cancer screening, the technology aims to increase diagnostic accuracy and reduce the disease’s preventable cases.
Funding
Funding not disclosed
Founders
Product
Problem
Current cervical cancer screening often relies on visual inspection during colposcopy without tissue sampling, leading to missed or delayed detection of precancerous lesions. The lack of a minimally invasive, routine biopsy method limits diagnostic accuracy and early intervention opportunities.
Solution
LumiPath provides a compact, minimally invasive biopsy device designed to be used during standard colposcopy examinations. The tool enables clinicians to obtain targeted cervical tissue samples quickly and comfortably, facilitating histopathological analysis of suspicious areas. By integrating the device into existing screening workflows, it allows for routine sampling without extending procedure time or requiring specialized training. Early and accurate detection of precancerous lesions supports timely treatment decisions, aiming to reduce the incidence of preventable cervical cancer.
Target Audience
Primary customers are gynecologists, colposcopists, and women's health clinics that perform routine cervical cancer screening and require reliable tissue sampling capabilities.
Features
- Needle‑based biopsy cartridge that fits within the colposcope’s working channel for seamless integration
- Single‑use, sterile design to maintain infection control and simplify workflow
- Low‑force insertion mechanism that minimizes patient discomfort while obtaining adequate tissue cores
- Compatibility with standard histology processing pipelines for reliable pathological assessment
- Real‑time visual feedback during sampling to ensure accurate targeting of lesions